Size : | Price | Quantity | |
---|---|---|---|
5 mg | $35.00 | ||
25 mg | $110.00 |
Pirfenidone (53179-13-8) is an antifibrotic agent. Prevents lung fibrosis in bleomycin-induced animal models.1 Down-regulates bleomycin-induced overexpression of lung procollagen I and III genes.2 Up-regulates RGS2 (Regulator of G-protein Signaling 2) which represents a new mechanism of pirfenidone action.3 Inhibits fibroblast proliferation.4 Suppresses TNFα production at the translational level.5 Scavenges hydroxyl radicals and inhibits lipid peroxidation in a dose-dependent manner.6 Recently approved therapeutic agent for idiopathic pulmonary fibrosis.7 Orally active.
References/Citations:
1) Kehrer and Margolin (1997), Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice; Toxicol.Lett., 90 125
2) Iyet et al. (1999), Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis; J.Pharmacol.Exp.Ther., 289 211
3) Xie et al. (2002), Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis; Respir.Res., 17 103
4) Li et al. (2016), Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-b signaling in a murine colitis model; Biochem.Pharmacol., 117 57
5) Nakazato et al. (2002), A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level, Eur.J.Pharmacol. 446 177
6) Misra and Rabideau (2000), Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals, Mol.Cell Biochem. 204 119
7) Canestaro et al. (2016), Drug Treatment of Idiopathic Pulmonary Fibrosis: Systemic Review and Network Meta-Analysis; Chest, 149 756
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Pirfenidone (53179-13-8) is an antifibrotic agent. Prevents lung fibrosis in bleomycin-induced animal models.1 Down-regulates bleomycin-induced overexpression of lung procollagen I and III genes.2 Up-regulates RGS2 (Regulator of G-protein Signaling 2) which represents a new mechanism of pirfenidone action.3 Inhibits fibroblast proliferation.4 Suppresses TNFα production at the translational level.5 Scavenges hydroxyl radicals and inhibits lipid peroxidation in a dose-dependent manner.6 Recently approved therapeutic agent for idiopathic pulmonary fibrosis.7 Orally active.
References/Citations:
1) Kehrer and Margolin (1997), Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice; Toxicol.Lett., 90 125
2) Iyet et al. (1999), Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis; J.Pharmacol.Exp.Ther., 289 211
3) Xie et al. (2002), Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis; Respir.Res., 17 103
4) Li et al. (2016), Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-b signaling in a murine colitis model; Biochem.Pharmacol., 117 57
5) Nakazato et al. (2002), A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level, Eur.J.Pharmacol. 446 177
6) Misra and Rabideau (2000), Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals, Mol.Cell Biochem. 204 119
7) Canestaro et al. (2016), Drug Treatment of Idiopathic Pulmonary Fibrosis: Systemic Review and Network Meta-Analysis; Chest, 149 756
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.